 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
6 News |  |
- ||||||| CS20AT04 / CoreStem
Trial completion: Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - Nov 6, 2024
P=N/A, N=6, Completed, Sponsor: Corestemchemon, Inc.
Active, not recruiting --> Completed
- ||| CS20AT04 / CoreStem
Trial completion date: Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - Mar 2, 2024
P=N/A, N=7, Active, not recruiting, Sponsor: Corestemchemon, Inc.
Active, not recruiting --> Completed Trial completion date: Jan 2024 --> May 2024
- || bone marrow-derived mesenchymal stem cells / CoreStem
P1 data, Preclinical, Journal: Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. (Pubmed Central) - Sep 10, 2022
P1
We defined the characteristics of BM-MSCs and identified their safety and tolerability in both animal models and a phase I clinical trial. The maximum tolerated dose was determined to be 3.0×10 cells/kg in patients with LN.
- CS20AT04 / CoreStem
New P2 trial: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - Apr 8, 2021
P2, N=10, Recruiting, Sponsor: Hanyang University Seoul Hospital
- | CS20AT04 / CoreStem
Enrollment closed: Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - Aug 24, 2020
P=N/A, N=7, Active, not recruiting, Sponsor: Corestem, Inc.
The maximum tolerated dose was determined to be 3.0×10 cells/kg in patients with LN. Recruiting --> Active, not recruiting
- |||||| CS20AT04 / CoreStem
New trial: Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - Aug 20, 2020
P, N=7, Recruiting, Sponsor: Corestem, Inc.
- CS20AT04 / CoreStem
[VIRTUAL] SAFETY OF CS20AT04, A HAPLOIDENTICAL ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, IN A PHASE 1 STUDY IN LUPUS NEPHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_1314;
P1
Recruiting --> Active, not recruiting CS20AT04 was well tolerated in single dose up to 3.0 x 106 cells/kg in patients with lupus nephritis.
- || CS20AT04 / CoreStem
Trial completion, Trial completion date, Trial primary completion date: Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis (clinicaltrials.gov) - Nov 20, 2019
P1, N=7, Completed, Sponsor: Corestem, Inc.
CS20AT04 was well tolerated in single dose up to 3.0 x 106 cells/kg in patients with lupus nephritis. Trial completion date: Jul 2018 --> Aug 2019 | Enrolling by invitation --> Completed | Trial primary completion date: Jun 2018 --> Mar 2019
- CS20AT04 / CoreStem
New P1 trial: Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis (clinicaltrials.gov) - Jun 1, 2017
P1, N=6, Enrolling by invitation, Sponsor: Corestem, Inc.